Biogen (BIIB) EBT (2009 - 2026)

Biogen (BIIB) has reported EBT for 18 consecutive years, with $377.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBT rose 21.37% year-over-year to $377.7 million; the TTM figure through Mar 2026 stood at $1.6 billion (down 7.38% YoY), while the FY2025 annual figure was $1.6 billion, down 18.34% from the prior year.
• EBT came in at $377.7 million for Q1 2026 at Biogen, up from -$56.0 million in the prior quarter.
• The five-year high for EBT was $1.4 billion in Q3 2022, with the low at -$141.2 million in Q3 2023.
• Average EBT over 5 years is $513.5 million, with a median of $451.0 million recorded in 2024.
• Across the five-year window, EBT jumped 419.41% in 2024 and slumped 119.21% in 2025, its largest moves.
• Year by year, EBT stood at $603.8 million in 2022, then sank by 51.71% to $291.6 million in 2023, then dropped by 0.03% to $291.5 million in 2024, then sank by 119.21% to -$56.0 million in 2025, then soared by 774.46% to $377.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $377.7 million, -$56.0 million, and $557.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.